In this issue of Clinical Cancer Research, the paper of Kenkre et al (1) investigated the influence of FcγRIIIa-V158F and FcγRIIa-H131R polymorphisms to predict response to rituximab. FCGR3A polymorphism's story began in 1997, when two different teams described for the first time a polymorphism located at amino acid residue 158 of FcγRIIIa leading to a substitution of a phenylalanine (F) with valine (V) that bound more efficiently to human IgG1 (2, 3) . Concurrently, rituximab (MabThera ® ), a chimeric IgG1 directed against CD20, was approved in the treatment of indolent lymphoma and emerged as a paradigm changing therapy for CD20 expressing lymphomas and lymphoproliferative disorders. At this time, little was known on how rituximab works in vivo and it was speculated that rituximab induces both Fv-(apoptosis) and Fc-mediated effects (ADCC, CDC and ADPC; see Figure 1 ). Because of rituximab shares similar Fc portion than human IgG1 and, monocytes and NK cells, the main actors of ADCC, express FcγRIIIa, we hypothesised and demonstrated that FcγRIIIa V/V allotype was associated with better response and/or outcome to rituximab in patients with untreated/relapsed follicular lymphoma (4, 5) . Similar results have been reproduced with rituximab in other clinical indications and also with other humanized IgG1 antibody such as trastuzumab (6) and cetuximab (7) . All these works underlined the role of ADCC in the mechanism of action of these antibodies and also opened a new area for the optimization of therapeutic monoclonal antibodies via an increased affinity for FcγRIIIa either by mutation of amino-acid residues of Fc portion involved in Fc-FcγRIIIa interaction or by modification of the oligosaccharide located between the two Fc arms. Two of these glycoengineered mAbs are currently in clinical development (ublituximab, TG Therapeutics and obinutuzumab, Roche Genentech). Recently, a multicentric phase III trial, demonstrated that obinutuzumab significantly increased response rate, molecular response and progression-free survival compared to rituximab when associated with chlorambucil for unfit CLL patients (8) . Those results would validate the clinical interest of mAbs with increased ADCC. However, the causal relationship between the optimized mechanism of action and clinical efficacy is not a straight line.
Curves include that FcγRIIIa-V158F polymorphism has not been shown to influence response to rituximab in CLL patients, and secondly, obinutuzumab's mechanism, as determined in vitro, is unique relative to rituximab with increased direct cytotoxic death and a lack of CDC. It is therefore difficult to discern the role of each mechanism (ADCC or direct cytotoxic death) in the observed clinical efficacy, which may also be questioned if the improved response rates translate to clinical benefit, as concluded in the recently reported, final results of the phase II GAUSS study (9).
In this context, Kenkre et al investigated the influence of FcγRIIIa-V158F and FcγRIIa-H131R polymorphisms to predict response to rituximab. In our opinion, the response is simply none of clinical import. The predictive value of such tests is not sufficiently strong to avoid rituximab therapy for those patients exhibiting unfavourable genotype. For example, in the seminal paper, 67% of F-carriers patients experience response to rituximab (4). Building upon prior critical evaluation, we argue that rituximab remains a viable option for this patient subset as well (4) . polymorphism and response to R-CHOP, the frequency of VV patients was 47%, compared to 15% in Caucasian population. Such distribution could contribute to favour patient groups exhibiting a better response to rituximab leading to statistical difference in some studies which will be not seen with lower allotype frequency.
Research. In vitro studies clearly demonstrated that rituximab is also able to induce ADPC, CDC and direct apoptosis. All these mechanisms could be influenced by different factors depending on tumor cells, host-or antibody-related factors. For example, CD20 mutation/epitope can influence binding 
